1007882-17-8

Upstream product

• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 5467-72-1 α-amino-4-bromoacetophenone hydrochloride 
• 1007882-38-3 (S)-benzyl 2-((2-(4-bromophenyl)-2-oxoethyl)carbamoyl)pyrrolidine-1-carboxylate 
• 1180671-39-9 1-benzyl-2-[2-(4-bromophenyl)-2-oxoethyl] (2S)-pyrrolidine-1,2-dicarboxylate 
• 1007882-39-4 (S)-benzyl 2-(5-(4-bromophenyl)-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 73183-34-3 bis(pinacol)diborane 

Downstream Products

• 1352212-78-2 benzyl (2S)-2-{5-[4-(5-bromopyrimidin-2-yl)phenyl]-1H-imidazol-2-yl}pyrrolidine-1-carboxylate 
• 1428136-88-2 C₄₂H₄₆N₆O₄Si 

Relevant academic research and scientific papers

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

HEPATITIS C VIRUS INHIBITORS

The present invention relates to compounds of the formula (I) and pharmaceutically acceptable salts thereof; to compositions containing such compounds; and to the of such compounds as inhibitors of HCV replication.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to (4-4' -diimidazolyl) biphenyls compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.